Last year's acting attorney general and a current judicial nominee has returned to Sidley Austin LLP after a six-year stint at the U.S. Department of Justice, where he oversaw False Claims Act litigation and off-label investigations.
Cozen O'Connor has added federal-prosecutor-turned-defense-lawyer Iden Grant Martyn to the firm's white-collar and complex criminal defense practice in Washington, D.C.
The U.S. subsidiary of Japanese pharmaceutical company Otsuka Pharmaceutical Co. Ltd. has agreed to pay $4 million to settle off-label marketing allegations brought by the U.S. Department of Justice.
Grant & Eisenhofer PA has launched a whistleblower litigation practice group, hiring two new attorneys, Reuben A. Guttman and Ann Lugbill, to open a new office for the firm in Washington, D.C. Much of its work will focus on pharmaceutical companies, who can be sued for defrauding government regulators in getting their products approved, and defense contractors, the firm said.
The U.S. government is fighting moves by Abbott Laboratories Inc. to question federal health officials a second time as part of its defense against claims in the massive antitrust litigation alleging an industry conspiracy to artificially inflate wholesale drug prices.
A federal district judge has partially denied Abbott Laboratories' bid to dismiss fresh claims brought by the U.S. government, as the massive antitrust litigation that alleges a group of pharmaceutical giants conspired to artificially inflate prescription drugs prices continues to roll along.
In an effort to increase its cartel enforcement, the United Kingdom's Office of Fair Trade announced it will begin offering rewards for whistleblowers of up to £100,000 ($198,530) during an 18-month trial period, after which it will decide whether to continue the policy.
An appeals court has affirmed several lower court decisions dismissing multiple lawsuits brought by a man who alleged that various medical systems had violated the Medicare Secondary Payer Act.
In a whistleblower case over Pfizer Inc.’s alleged illegal marketing of human growth hormone Genotropin, a judge has denied Pfizer Inc.’s bid to force a former executive to turn over information as to whether he made adequate efforts to look for work after he was fired.
After months of fighting, Eli Lilly & Co. has won its bid to combine a California whistleblower case alleging it marketed its blockbuster anti-psychotic drug Zyprexa for off-label uses with a separate multidistrict litigation pending in a New York district court.
Proposed class action suits are piling up against Merck & Co. and Schering-Plough Corp., claiming the drugmakers broke state consumer protection laws through the sale and marketing of cholesterol-lowering drugs Vytorin and Zetia.
Merck & Co. will pay more than $650 million to settle False Claims Act suits that accused the company of overcharging Medicare and paying kickbacks to doctors to get them to dispense the drugs Mevacor, Vioxx, Zocor and Pepcid.
Wisconsin has suffered a blow in its case against Dey Inc. and others over average wholesale prices of pharmaceuticals, with an appeals court reversing the state's fee award and shooting down its request to award sanctions.
Merck & Co. and Schering-Plough Corp. face a rising tide of controversy over Vytorin, as the attorneys general of two states investigate whether the companies suppressed the results of a study that found that the drug worked no better than an older, cheaper drug to prevent the buildup of arterial plaque.
A District of Columbia federal judge has barred the nonprofit group Project on Government Oversight from presenting evidence regarding allegedly illegal payments made to a government employee in a whistleblower action against oil companies.
Health care attorneys and their clients will be watching everything from the high court to the New York attorney general's office for precedent-setting litigation and bellwether regulation in 2008. Attorneys said that such diverse issues as the taxation of nonprofit hospitals, Medicaid reimbursement and product liability litigation will be on their minds this year.
In a boost to Eli Lilly & Co., a federal judge has granted the pharmaceutical giant's bid to stay a whistleblower suit over charges it marketed its blockbuster anti-psychotic drug Zyprexa for off-label uses.
Two whistleblowers will split almost $3 million as a result of Stryker Corp. agreeing to shell out $16.6 million to resolve allegations that Physiotherapy Associates Inc. — formerly a unit of Stryker — submitted false claims to federal health care programs, the U.S. Department of Justice said on Wednesday.
A federal appeals court has vacated the dismissal of a whistleblower suit filed by a former Pfizer Inc. executive over the drug giant's alleged illegal marketing of human growth hormone Genotropin so that a lower court can consider an amended complaint.
The five major makers of artificial joints revealed that they have paid more than $200 million so far this year to doctors and hospitals as part of an agreement with the U.S. Department of Justice.